106 related articles for article (PubMed ID: 11362873)
1. Symptom-reduction trials at FDA clinical trials workshop. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Sep; (no 231):7. PubMed ID: 11362873
[TBL] [Abstract][Full Text] [Related]
2. FDA workshop on clinical trial design, September 6-7--registration by Aug. 18. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Aug; (no 228):5-6. PubMed ID: 11362627
[TBL] [Abstract][Full Text] [Related]
3. FDA community meeting May 16: clinical trials and viral load. Food and Drug Administration.
AIDS Treat News; 1997 May; (No 270):3. PubMed ID: 11364324
[TBL] [Abstract][Full Text] [Related]
4. FDA evaluates accelerated approval process. Food and Drug Administration.
Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
[TBL] [Abstract][Full Text] [Related]
5. FDA advisory committees meet January 26 on Salk HIV-1 immunogen.
AIDS Treat News; 1995 Jan; (No 214):1-2. PubMed ID: 11362184
[TBL] [Abstract][Full Text] [Related]
6. Let there be drugs.
Gilden D
GMHC Treat Issues; 1996 Feb; 10(2):1, 13-6. PubMed ID: 11363380
[TBL] [Abstract][Full Text] [Related]
7. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
Feigal D
AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
[TBL] [Abstract][Full Text] [Related]
8. IRB/FDA requirements relevant to HIV/AIDS clinical trials in correctional settings.
Cohen J;
AIDS Read; 2001 Jan; 11(1):41-2. PubMed ID: 11215087
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials and viral load: statement for FDA community meeting May 16. Food and Drug Administration.
James JS
AIDS Treat News; 1997 May; (No 271):1-4. PubMed ID: 11364367
[TBL] [Abstract][Full Text] [Related]
11. "Confirmatory" trials: symptom reduction as efficacy measure.
James JS
AIDS Treat News; 1995 Aug; (no 229):1-5. PubMed ID: 11362629
[TBL] [Abstract][Full Text] [Related]
12. FDA clarifies rules, allows combining antiretrovirals in clinical trials. Food and Drug Administration.
AIDS Treat News; 1999 Nov; (No 331):5-6. PubMed ID: 11367127
[TBL] [Abstract][Full Text] [Related]
13. Editorial: time to end the death trials.
James JS
AIDS Treat News; 1996 Aug; (no 252):1-4. PubMed ID: 11363751
[TBL] [Abstract][Full Text] [Related]
14. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
[TBL] [Abstract][Full Text] [Related]
15. New drug approved to treat HIV.
Treat Rev; 1997 Apr; (No 24):5. PubMed ID: 11364284
[TBL] [Abstract][Full Text] [Related]
16. [Improving resistance profile, simplifying administration mode. New antiretroviral drugs].
Arastéh K; Müller M
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():66-70. PubMed ID: 12043080
[TBL] [Abstract][Full Text] [Related]
17. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
18. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine approved by FDA for treatment of AIDS.
Clin Pharm; 1987 Jun; 6(6):431,435. PubMed ID: 3319360
[No Abstract] [Full Text] [Related]
20. Clinical trial that led to FDA approval of zidovudine is published.
Clin Pharm; 1987 Oct; 6(10):752. PubMed ID: 3333341
[No Abstract] [Full Text] [Related]
[Next] [New Search]
